ArticleBMC pharmacology & toxicology2026
Development and validation of a nomogram for predicting thrombocytopenia in sepsis patients treated with linezolid.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe incidence of thrombocytopenia in sepsis patients treated with linezolid is higher, and the mortality rate is significantly increased. This study aimed to develop and validate a nomogram for predicting thrombocytopenia in sepsis patients treated with linezolid.
methodsData were retrospectively collected from the MIMIC-IV database. Patients were randomly divided into a training cohort and a validation cohort in a 7:3 ratio. Variables were selected using Least Absolute Shrinkage and Selection Operator regression and logistic regression analysis. A nomogram model was subsequently established from the training set and evaluated using decision curve analysis, calibration curves, and receiver operating characteristic (ROC) curves.
resultsA total of 276 patients were included in the study, of whom 87 developed thrombocytopenia. Gender, cirrhosis, use of immunosuppressants, total dosage of linezolid and antiepileptic drugs, blood ureanitrogen level, mechanical ventilation duration, and SOFA scores were identified as independent risk factors for thrombocytopenia in sepsis patients treated with linezolid. The nomogram constructed using these eight factors had an AUC of 0.88 in the training set and an AUC of 0.73 in the validation set. Calibration curves showed good agreement between the model and actual observations. Decision curve analysis indicated that using the nomogram to predict the risk of thrombocytopenia would be highly beneficial if the threshold in the training set was between 0.05 and 0.95, and between 0.20 and 0.90 in the validation set.
conclusionThe nomogram demonstrated excellent predictive performance for thrombocytopenia in sepsis patients treated with linezolid and can serve as a reference for clinical decision-making. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.